BSH 2019 | Preclinical results of a CD200-directed antibody in AML

Namrata Rastogi

CD200 is an important immune checkpoint protein, whose expression is associated with poor prognosis. Here, Namrata Rastogi, PhD, Cardiff University, Cardiff, UK, discusses the promising preclinical investigation of a CD200 blocking antibody in acute myeloid leukemia (AML) and exciting plans for a Phase I trial. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

Share this video